Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 3/20 | 0.47 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.45 |
| ▸ | KCNQ3 | O43525 | 3/20 | 0.43 |
| ▸ | KCNQ2 | O43526 | 3/20 | 0.43 |
| ▸ | KCNQ4 | P56696 | 2/20 | 0.43 |
| ▸ | KCNQ5 | Q9NR82 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL462816 | 0.95 | AR (0.47) | ARNLRP3KCNQ3KCNQ2KCNQ4 | |
| SCHEMBL404508 | 0.87 | NLRP3 (0.51) | ARNLRP3KCNQ3KCNQ2KCNQ4 | |
| SCHEMBL405701 | 0.84 | NLRP3 (0.49) | NLRP3KCNQ3KCNQ2KCNQ4KCNQ5 | |
| SCHEMBL463098 | 0.84 | NLRP3 (0.44) | ARNLRP3CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL12225102 | 0.82 | NLRP3 (0.47) | ARNLRP3KCNQ3KCNQ2KCNQ4 | |
| SCHEMBL31422816 | 0.82 | NLRP3 (0.43) | ARNLRP3ALDH1A1GAAL3MBTL1 | |
| SCHEMBL406273 | 0.82 | NLRP3 (0.49) | ARNLRP3KCNQ3KCNQ2KCNQ4 | |
| SCHEMBL8333678 | 0.80 | ALDH1A1 (0.50) | ARNLRP3KCNQ3KCNQ2KCNQ4 | |
| SCHEMBL24825600 | 0.79 | SMN1; SMN2 (0.52) | NLRP3KCNQ3KCNQ2KCNQ4KCNQ5 | |
| SCHEMBL439922 | 0.79 | NLRP3 (0.52) | ARNLRP3KCNQ3KCNQ2KCNQ4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065187-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | ALCON RESEARCH, LTD (US) | 2012-03-15 | — | — | US | disclosed |
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20100120741-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120741-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120741-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | AR 2399/4885NLRP3 666/4885KCNQ3 1511/4885 |
| US-20120065187-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | AR 2399/4885NLRP3 666/4885KCNQ3 1511/4885 |
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | AR 2399/4885NLRP3 666/4885KCNQ3 1511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.